Cervical Cancer Screening Market: By Test Type (Pap Smear Tests, HPV Tests, LBC Tests, Others), and Geography

Cervical Cancer Screening Market was valued at USD 445.5 million in 2023 and is expected to grow at USD 463.3 million in 2030, to grow at a CAGR of 2.3% over 2024-2030. Cervical cancer is a malignancy that develops in the cervix, the lower part of the uterus. It's primarily caused by persistent human papillomavirus (HPV) infection. Initially asymptomatic, it can be detected early through regular screenings like Pap smears and HPV tests. If caught early, cervical cancer is highly treatable and often preventable through HPV vaccination. According to WHO Cervical cancer is the fourth most common cancer in women globally with around 6,60,000 new cases and around 3,50000 deaths in 2022. Cervical Cancer Screening Market is driven by increasing awareness and government initiatives. 

Furthermore, technological innovations are significantly driving the cervical cancer screening market forward. Traditional pap smears are being supplemented or replaced by more advanced techniques, for instance, liquid-based cytology, and HPV DNA testing, improving both the accuracy of screening and patient experience. The implementation of national screening programs in developing countries has significantly boosted market expansion. However, accessibility and affordability of screening services remain major challenges, especially in low-resource settings. Regulatory bodies like the WHO provide guidelines for cervical cancer screening, emphasizing the importance of quality assurance and appropriate follow-up care. North America region held the major market share in 2023 and is expected to dominate the global cervical cancer screening market in the forecasted years.

In addition, the increase in consumption of tobacco and alcohol among the female population, the surge in the prevalence of HPV infection, increase in the incidence of unsafe sex also boost the market over the forecast timeframe. The development of newer tests to diagnose cervical cancer more efficiently the expansion of the business into low-income markets and the high prevalence of cervical cancer countries create some opportunities for marketers. In the cervical cancer screening market, the pap smear tests segment is estimated to lead the global cervical cancer screening market in 2022, in terms of value and volume, owing to increased government funding and insurance coverage.

Cervical Cancer Screening Market Key Developments:

In Jun 2022, Roche launched a human papillomavirus (HPV) self-sampling tool, expanding cervical cancer screening choices.

• The tool allows individuals to collect their samples for human papillomavirus (HPV) testing. HPV is the primary cause of cervical cancer.
• Self-sampling tool increases accessibility by making it easier for people to get screened, especially those who face barriers to traditional clinical exams.

In April 2024, QIAGEN N.V., a biotechnology company, launched various novel products:

• QIAcuity dPCR PanCancer Kits: These kits use digital PCR (dPCR) technology and, designed to study multiple types of cancer.
• QIAseq Targeted RNA-seq Panel for T-cell receptors: This panel uses RNA sequencing technology.
• PAXgene Urine Liquid Biopsy Set: It facilitates urine collection and stabilization as a novel liquid biopsy technique and to further advance cancer research.